H

HLB Inc
KOSDAQ:028300

Watchlist Manager
HLB Inc
KOSDAQ:028300
Watchlist
Price: 75 400 KRW 2.86% Market Closed
Market Cap: 9.9T KRW
Have any thoughts about
HLB Inc?
Write Note

HLB Inc
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HLB Inc
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
H
HLB Inc
KOSDAQ:028300
Cash Taxes Paid
-â‚©320.7m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SD Biosensor Inc
KRX:137310
Cash Taxes Paid
â‚©198.9B
CAGR 3-Years
527%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
BioPlus Co Ltd
KOSDAQ:099430
Cash Taxes Paid
â‚©8.4B
CAGR 3-Years
68%
CAGR 5-Years
144%
CAGR 10-Years
N/A
T
T&L Co Ltd
KOSDAQ:340570
Cash Taxes Paid
â‚©4.6B
CAGR 3-Years
46%
CAGR 5-Years
62%
CAGR 10-Years
N/A
H
Humasis Co Ltd
KOSDAQ:205470
Cash Taxes Paid
â‚©21.7B
CAGR 3-Years
212%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Interojo Co Ltd
KOSDAQ:119610
Cash Taxes Paid
â‚©3.9B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
4%
No Stocks Found

HLB Inc
Glance View

Market Cap
9.9T KRW
Industry
Health Care

HLB Inc. is a dynamic biopharmaceutical company dedicated to the discovery and development of innovative treatments for a range of serious diseases. Founded on the principles of scientific excellence and a commitment to patient care, HLB has quickly gained recognition for its robust portfolio of drug candidates targeting areas such as oncology, autoimmune diseases, and rare disorders. The company's strategic approach combines cutting-edge research with advanced clinical trials, leveraging partnerships with leading research institutions and healthcare organizations to propel its therapeutic innovations. With a strong financial backing and a clear vision for growth, HLB is not just about developing drugs; it’s about transforming patient outcomes and making a meaningful impact on global health. As an investor, HLB Inc. presents a compelling opportunity anchored in its core strengths: a seasoned management team with a proven track record, a rich pipeline of promising drug candidates, and a robust intellectual property portfolio that secures its market position. The company’s commitment to transparency and strategic operational decisions positions it well for sustainable growth in the competitive biopharmaceutical landscape. With the increasing demand for effective therapies and advancements in medical technology, HLB stands poised to unlock significant shareholder value while driving progress in medical treatment options. This compelling narrative of potential, combined with HLB's dedication to innovation, makes it an intriguing prospect for investors seeking exposure to the biopharmaceutical sector.

Intrinsic Value
880.61 KRW
Overvaluation 99%
Intrinsic Value
Price
H

See Also

What is HLB Inc's Cash Taxes Paid?
Cash Taxes Paid
-320.7m KRW

Based on the financial report for Sep 30, 2024, HLB Inc's Cash Taxes Paid amounts to -320.7m KRW.

What is HLB Inc's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 3Y
-48%

The average annual Cash Taxes Paid growth rates for HLB Inc have been -48% over the past three years .

Back to Top